Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody
Mehmet Akce, Yuan Liu, Katerina Zakka, et al.
American Journal of Clinical Oncology (2020) Vol. 44, Iss. 2, pp. 74-81
Closed Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta‐analysis
Yukinori Takenaka, Ryohei Oya, Norihiko Takemoto, et al.
Journal of Cachexia Sarcopenia and Muscle (2021) Vol. 12, Iss. 5, pp. 1122-1135
Open Access | Times Cited: 88
The Clinical Value of Nutritional Care before and during Active Cancer Treatment
Giuseppe Aprile, Debora Basile, R. Giaretta, et al.
Nutrients (2021) Vol. 13, Iss. 4, pp. 1196-1196
Open Access | Times Cited: 79
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
Bang‐Bin Chen, Po‐Chin Liang, Tiffany Ting‐Fang Shih, et al.
European Radiology (2022) Vol. 33, Iss. 1, pp. 512-522
Closed Access | Times Cited: 44
Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis
Yusheng Guo, Yanqiao Ren, Licheng Zhu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 30
Inflammatory Markers in Cancer Immunotherapy
Deepak Ravindranathan, Viraj A. Master, Mehmet Asım Bilen
Biology (2021) Vol. 10, Iss. 4, pp. 325-325
Open Access | Times Cited: 48
Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis
Paul Trinkner, Sophie Günther, Ina Monsef, et al.
European Journal of Cancer (2023) Vol. 184, pp. 151-171
Closed Access | Times Cited: 19
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Mathew Vithayathil, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 904-914
Open Access | Times Cited: 18
Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
Xianbin Wu, Runkun Han, Yanping Zhong, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 41
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Selina K. Wong, Caroline A. Nebhan, Douglas B. Johnson
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 40
Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy
Jie Mei, Xuqi Sun, Wen‐Ping Lin, et al.
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 3879-3890
Open Access | Times Cited: 38
Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study
Lushan Xiao, Rui-ning Li, Hao Cui, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
Hiroaki Matsumoto, Kaoru Tsuchiya, Hiroyuki Nakanishi, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3551-3551
Open Access | Times Cited: 23
Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
Ji Won Han, Jeong Won Jang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11799-11799
Open Access | Times Cited: 12
The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy
Jingzhong Ouyang, Yi Yang, Yanzhao Zhou, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1519-1531
Closed Access | Times Cited: 12
Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling
Jian Yang, Jialuo He, Yiting Feng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy
Hongcai Yang, Tianhao Cong, Yingen Luo, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 175-189
Open Access | Times Cited: 4
The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors
Wei Sun, Xue Yin, Xiaomin Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma
Jingjing Chen, Xueying Huang, Qiaoxin Wei, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Impact of body mass index in patients with hepatocellular carcinoma treated with TACE combined with lenvatinib and PD-1 inhibitors
Qishen Wang, Fang Liu, Chixiang Liu, et al.
ONCOLOGIE (2025)
Closed Access
Nutritional status in patients with hepatocellular carcinoma: Potential relevance for clinical outcome
Anne M. van Dijk, Bart J.P. Coppens, Maartje A. van Beers, et al.
European Journal of Internal Medicine (2022) Vol. 104, pp. 80-88
Open Access | Times Cited: 16
Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis
Meng‐Hsuan Kuo, Chih‐Wei Tseng, Ching‐Sheng Hsu, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2426-2426
Open Access | Times Cited: 8
Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma
Hong Liu, Xue-Mei Gan, Jianming Sun, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111510-111510
Open Access | Times Cited: 3
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Ran Qin, Tianqiang Jin, Feng Xu
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Prevalence of sarcopenia among patients with hepatocellular carcinoma: A systematic review and meta‑analysis
Jiye Liu, Han-Yong Luo, Le‐Tian Huang, et al.
Oncology Letters (2023) Vol. 26, Iss. 1
Open Access | Times Cited: 7
Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis
Xuanmei Li, Xue Huang, Lifu Lei, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top